Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

Product menu

DOSING & DRUG-DRUG INTERACTIONS

VOCABRIA + REKAMBYS: TWO MONTHS BETWEEN CONTINUATION DOSES1,2

BEFORE TREATMENT INITIATION1,2

  • Ensure patients agree to the required every-2-month dosing schedule and counsel patients about the importance of adherence to scheduled injection visits
  • Set a consistent injection date, the Target Treatment Date, to help keep your patients on track

EVERY-2-MONTH DOSING SCHEDULE1,2

EVERY-2-MONTH DOSING SCHEDULE

FOLLOWING TREATMENT DISCONTINUATION1,2

  • It is essential to start alternative ARV therapy no later than 2 months after the final injections (or 1 month if after first initiation injections) in order to minimise the risk of developing viral resistance

OPTIONAL ORAL LEAD-IN

If you would like to assess tolerability, prescribe 2 tablets (1 cabotegravir and 1 rilpivirine tablet) to be taken once daily with a meal for 1 month (at least 28 days).1,2

EVERY-2-MONTH DOSING WITH WITH ORAL LEAD-IN1,2

EVERY-2-MONTH DOSING WITH WITH ORAL LEAD-IN
  • When given the choice in SOLAR study, more participants and physicians chose to start with injections than via oral lead-in3

MANAGE MISSED INJECTIONS

  • If a patient plans to miss a scheduled injection visit by more than 7 days, oral cabotegravir (30 mg tablet) in combination with rilpivirine (25 mg tablet) once daily may be used for up to 2 consecutive months1,2
  • For durations greater than 2 months, an alternative oral regimen is recommended1,2
  • The first dose of oral therapy should be taken 2 months (+/- 7 days) after the last injection dose of every-2-month VOCABRIA + REKAMBYS and continued until the day injection dosing is restarted1,2

RESTARTING AFTER PLANNED MISSED INJECTIONS1,2

RESTARTING AFTER PLANNED MISSED INJECTIONS
  • Adherence to scheduled injection visits is important1,2
  • Clinically reassess the patient to determine whether long-acting treatment remains appropriate1,2

RESTARTING AFTER UNPLANNED MISSED INJECTIONS1,2

RESTARTING AFTER UNPLANNED MISSED INJECTIONS

IMPORTANT DRUG-DRUG INTERACTIONS1,2,4–6

Download

Which of your patients could benefit from two months between doses?

Click here

contact

Want to discuss further? Reach out to us

Anita Henriksen
Key Account Manager
anita.x.henriksen@gsk.com
Mobil: 995 25 487

Linda Marie Sørpebøl
Key Account Manager
lindamarie.x.sorpebol@gsk.com
Mobil: 952 32 576

ARV=antiretroviral; CYP3A=cytochrome P450 3A; GI=gastrointestinal; IM=intramuscular; OAT=organic anion transporter.

References
  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
  2. REKAMBYS Summary of Product Characteristics. Janssen-Cilag International NV.
  3. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety and tolerability of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV, 12 month results (SOLAR): A randomised open-label, phase 3b non-inferiority trial. Lancet HIV. 2023 Sep;10(9):e566-e577. Published Online 8th August 2023. https://doi.org/10.1016/S2352-3018(23)00136-4
  4. EDURANT Summary of Product Characteristics. Janssen-Cilag International NV.
  5. Antzelevitch C, Sun ZQ, Zhang ZQ, et al. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol. 1996;28(7):1836−1848. doi: 10.1016/S0735-1097(96)00377-4.
  6. Vieweg WVR, Hancox JC, Hasnain M, et al. Clarithromycin QTc interval prolongation and torsades de pointes: the need to study case reports. Ther Adv Infect Dis. 2013;1(4):121−138. doi: 10.1177/2049936113497203.

REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

5/2025, PM-NO-CBR-WCNT-250004